Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
[18] Lactation studies demonstrate that maternal injections modestly elevate breast-milk B12 concentrations without adverse infant outcomes, supporting compatibility with breastfeeding while underscoring the need for maternal repletion to prevent neonatal deficiency
Preclinical Safety Evaluation In preclinical studies, BPC 157 did not lead to any serious toxicity in tested animals, including: mice rats rabbits dogs These studies provide a strong foundation for understanding the safety profile of BPC 157, indicating that it is well-tolerated across different species
Drug interactions remain incompletely characterized
Given its regenerative properties and favorable safety profile, AOD9604 holds promise as a novel therapeutic agent for OA, especially when used in conjunction with established treatments like HA [1]
US$ 27.67
US$ 24.26
US$ 20.88
US$ 28.29
.png)
US$ 22.38
